Study of Dose-Dense Adriamycin Plus Cytoxan (AC) Followed by Either Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
This study is ongoing, but not recruiting participants.
Study NCT00394251
Information provided by Abraxis BioScience Inc.
First Received: October 30, 2006
Last Updated: March 24, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
